Ronapreve is a medicine used for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of their disease becoming severe. The medicine can also be used to prevent COVID-19 in people aged 12 years and older weighing at least 40 kilograms. Ronapreve contains two active substances, casirivimab and imdevimab.
Therapeutic Indication
### Therapeutic indication Ronapreve is indicated for: - Treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 (see section 4.2). - Prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4.2). The use of Ronapreve should take into account information on the activity of Ronapreve against viral variants of concern. See sections 4.4 and 5.1.
Therapeutic Area (MeSH)
N/AATC Code
J06BD07
ATC Item
casirivimab and imdevimab
Pharmacotherapeutic Group
Immune sera and immunoglobulins
Active Substance (Summary)
N/AINN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| casirivimab | N/A | Casirivimab |
| imdevimab | N/A | Imdevimab |
EMA Name
Ronapreve
Medicine Name
Ronapreve
Aliases
N/ANo risk management plan link.
